Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2015, Article ID 847373, 10 pages
http://dx.doi.org/10.1155/2015/847373
Research Article

Proteasome Inhibitor Bortezomib Suppresses Nuclear Factor-Kappa B Activation and Ameliorates Eye Inflammation in Experimental Autoimmune Uveitis

1Institute of Clinical Medicine, College of Medicine, National Cheng-Kung University, No. 35, Siao-Dong Road, Tainan 70403, Taiwan
2Department of Ophthalmology, National Cheng-Kung University Hospital, Tainan 70403, Taiwan
3Department of Ophthalmology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei 10051, Taiwan
4Department of Microbiology and Immunology, College of Medicine, National Cheng-Kung University, Tainan 70101, Taiwan
5Department of Pediatrics, National Cheng-Kung University Hospital, Tainan 70403, Taiwan

Received 16 May 2014; Revised 5 September 2014; Accepted 7 September 2014

Academic Editor: Andrzej Grzybowski

Copyright © 2015 Sheng-Min Hsu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Wakefield and J. H. Chang, “Epidemiology of uveitis,” International Ophthalmology Clinics, vol. 45, no. 2, pp. 1–13, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. R. R. Caspi, “A look at autoimmunity and inflammation in the eye,” Journal of Clinical Investigation, vol. 120, no. 9, pp. 3073–3083, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. R. Horai and R. R. Caspi, “Cytokines in autoimmune uveitis,” Journal of Interferon and Cytokine Research, vol. 31, no. 10, pp. 733–744, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. J. V. Forrester, I. P. Klaska, T. Yu, and L. Kuffova, “Uveitis in mouse and man,” International Reviews of Immunology, vol. 32, no. 1, pp. 76–96, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. F. Gasparin, B. S. Takahashi, M. R. Scolari, F. Gasparin, L. S. Pedral, and F. M. Damico, “Experimental models of autoimmune inflammatory ocular diseases,” Arquivos Brasileiros de Oftalmologia, vol. 75, no. 2, pp. 143–147, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. D. Iwata, N. Kitaichi, A. Miyazaki et al., “Amelioration of experimental autoimmune uveoretinitis with nuclear factor-κB inhibitor dehydroxy methyl epoxyquinomicin in mice,” Investigative Ophthalmology & Visual Science, vol. 51, no. 4, pp. 2077–2084, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. H. Kitamei, K. Iwabuchi, K. Namba et al., “Amelioration of experimental autoimmune uveoretinitis (EAU) with an inhibitor of nuclear factor-κB (NF-κB), pyrrolidine dithiocarbamate,” Journal of Leukocyte Biology, vol. 79, no. 6, pp. 1193–1201, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. B. Skaug, X. Jiang, and Z. J. Chen, “The role of ubiquitin in NF-kappaB regulatory pathways,” Annual Review of Biochemistry, vol. 78, pp. 769–796, 2009. View at Google Scholar
  9. T. D. Gilmore, “Introduction to NF-κB: players, pathways, perspectives,” Oncogene, vol. 25, no. 51, pp. 6680–6684, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. A. M. Gomez, K. Vrolix, P. Martínez-Martínez et al., “Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis,” The Journal of Immunology, vol. 186, no. 4, pp. 2503–2513, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. T. M. Zollner, M. Podda, C. Pien, P. J. Elliott, R. Kaufmann, and W.-H. Boehncke, “Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model,” The Journal of Clinical Investigation, vol. 109, no. 5, pp. 671–679, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Yannaki, A. Papadopoulou, E. Athanasiou et al., “The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant-induced arthritis in rats,” Arthritis and Rheumatism, vol. 62, no. 11, pp. 3277–3288, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. C. L. Vanderlugt, S. M. Rahbe, P. J. Elliott, M. C. Dal Canto, and S. D. Miller, “Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519,” Journal of Autoimmunity, vol. 14, no. 3, pp. 205–211, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. D. J. Lee and A. W. Taylor, “Both MC5r and A2Ar are required for protective regulatory immunity in the spleen of post-experimental autoimmune uveitis in mice,” Journal of Immunology, vol. 191, no. 8, pp. 4103–4111, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. K. Namba, N. Kitaichi, T. Nishida, and A. W. Taylor, “Induction of regulatory T cells by the immunomodulating cytokines α-melanocyte-stimulating hormone and transforming growth factor-β2,” Journal of Leukocyte Biology, vol. 72, no. 5, pp. 946–952, 2002. View at Google Scholar · View at Scopus
  16. R. K. Agarwal and R. R. Caspi, “Rodent models of experimental autoimmune uveitis,” Methods in Molecular Medicine, vol. 102, pp. 395–419, 2004. View at Google Scholar · View at Scopus
  17. F.-T. Chen, Y.-C. Liu, C.-M. Yang, and C.-H. Yang, “Anti-inflammatory effect of the proteasome inhibitor bortezomib on endotoxin-induced uveitis in rats,” Investigative Ophthalmology and Visual Science, vol. 53, no. 7, pp. 3682–3694, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. M. Busch, D. Bauer, M. Hennig, S. Wasmuth, S. Thanos, and A. Heiligenhaus, “Effects of systemic and intravitreal TNF-α inhibition in experimental autoimmune uveoretinitis,” Investigative Ophthalmology & Visual Science, vol. 54, no. 1, pp. 39–46, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. G. Levy-Clarke, D. A. Jabs, R. W. Read, J. T. Rosenbaum, A. Vitale, and R. N. Van Gelder, “Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders,” Ophthalmology, vol. 121, no. 3, pp. 785.e3–796.e3, 2014. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. K. N. Utecht and J. Kolesar, “Bortezomib: a novel chemotherapeutic agent for hematologic malignancies,” American Journal of Health-System Pharmacy, vol. 65, no. 13, pp. 1221–1231, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. J. S. Miguel, J. Bladé, M. Boccadoro et al., “A practical update on the use of bortezomib in the management of multiple myeloma,” Oncologist, vol. 11, no. 1, pp. 51–61, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. D. Sánchez-Cano, J. L. Callejas-Rubio, R. Ruiz-Villaverde, R. Ríos-Fernández, and N. Ortego-Centeno, “Off-label uses of anti-TNF therapy in three frequent disorders: behçet's disease, sarcoidosis, and noninfectious uveitis,” Mediators of Inflammation, vol. 2013, Article ID 286857, 10 pages, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. E. Tobinick, “Perispinal etanercept: a new therapeutic paradigm in neurology,” Expert Review of Neurotherapeutics, vol. 10, no. 6, pp. 985–1002, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. R. Brambilla, J. J. Ashbaugh, R. Magliozzi et al., “Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination,” Brain, vol. 134, part 9, pp. 2736–2754, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. L. Song, J. Le, F. Ye, H. Shao, H. J. Kaplan, and D. Sun, “Sequence 168 to 177 of interphotoreceptor retinoid-binding protein (IRBP) is an antigenic epitope for autoreactive CD8 T cells in the B10RIII mouse,” Journal of Neuroimmunology, vol. 193, no. 1-2, pp. 68–76, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. J. Wu, “On the role of proteasomes in cell biology and proteasome inhibition as a novel frontier in the development of immunosuppressants,” The American Journal of Transplantation, vol. 2, no. 10, pp. 904–912, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. P.-M. Kloetzel and F. Ossendorp, “Proteasome and peptidase function in MHC-class-I-mediated antigen presentation,” Current Opinion in Immunology, vol. 16, no. 1, pp. 76–81, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. L. H. Mattingly, R. A. Gault, and W. J. Murphy, “Use of systemic proteasome inhibition as an immune-modulating agent in disease,” Endocrine, Metabolic and Immune Disorders—Drug Targets, vol. 7, no. 1, pp. 29–34, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. H. Shao, Y. Peng, T. Liao et al., “A shared epitope of the interphotoreceptor retinoid-binding protein recognized by the CD4+ and CD8+ autoreactive T cells,” The Journal of Immunology, vol. 175, no. 3, pp. 1851–1857, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. Y. Yang, J. Kitagaki, H. Wang, D.-X. Hou, and A. O. Perantoni, “Targeting the ubiquitin-proteasome system for cancer therapy,” Cancer Science, vol. 100, no. 1, pp. 24–28, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. J. Adams, “The development of proteasome inhibitors as anticancer drugs,” Cancer Cell, vol. 5, no. 5, pp. 417–421, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Adams, “The proteasome: a suitable antineoplastic target,” Nature Reviews Cancer, vol. 4, no. 5, pp. 349–360, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. E. Moran, F. Carbone, V. Augusti, F. Patrone, A. Ballestrero, and A. Nencioni, “Proteasome inhibitors as immunosuppressants: biological rationale and clinical experience,” Seminars in Hematology, vol. 49, no. 3, pp. 270–276, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus